Equities
Health CareMedical Equipment and Services
  • Price (USD)18.12
  • Today's Change0.128 / 0.71%
  • Shares traded21.59k
  • 1 Year change+32.02%
  • Beta0.8064
Data delayed at least 15 minutes, as of Sep 18 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Olympus Corp is a Japan-based company mainly engaged in the manufacture and sale of endoscopes, therapeutic equipment, scientific and other products. The Company operates through three business segments. The Endoscope segment provides gastrointestinal endoscopes, surgical endoscopes, and medical services. The Therapeutic Equipment segment provides gastrointestinal treatment instruments, urology products, respiratory products, energy devices, otolaryngology products and gynecology products. The Others segment provides biomaterials and orthopedic instruments. The Company is also engaged in the business activities, including holding companies and financial investments related to each business.

  • Revenue in USD (TTM)6.76bn
  • Net income in USD196.38m
  • Incorporated1919
  • Employees28.84k
  • Location
    Olympus Corp2951, Ishikawa-machiHACHIOJI-SHI 192-8507JapanJPN
  • Phone+81 426422111
  • Fax+81 333402062
  • Websitehttps://www.olympus.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Revvity Inc2.71bn197.34m15.13bn11.50k76.831.9224.165.591.601.3721.9063.800.19592.894.42235,499.601.434.761.595.3955.2657.197.2915.341.986.890.32996.52-16.95-0.1982-64.99-5.28-2.690.00
Insulet Corp1.87bn395.30m16.52bn3.00k43.5216.5435.088.825.415.4124.5314.240.7111.386.25624,233.3015.012.7118.153.1469.0065.8121.114.282.7187.970.58330.0030.0224.664,384.78128.77-7.63--
Avantor Inc6.83bn360.20m18.27bn14.50k50.753.3624.002.680.52950.529510.038.000.5305.375.82470,731.002.802.973.173.3533.7133.445.285.061.053.070.48480.00-7.263.51-51.52--31.17--
Align Technology, Inc.3.94bn447.03m18.91bn21.61k42.945.0332.224.805.905.9052.0350.310.6414.164.09182,455.407.2716.3410.9624.1469.8271.7211.3423.161.06--0.000.003.4214.4523.092.15-4.46--
Hologic Inc3.99bn701.50m19.05bn6.99k27.983.8418.834.782.932.9316.5921.330.43752.646.06570,472.107.7011.408.6413.3855.4160.2917.5920.953.32709.770.34080.00-17.124.61-64.98--7.30--
Waters Corp2.88bn595.69m19.53bn7.90k32.7713.8324.806.7910.0410.0448.4623.790.63942.194.41364,118.2013.2419.7716.0425.2959.6858.4520.7123.381.428.740.58690.00-0.52294.09-9.261.534.72--
Baxter International Inc15.00bn-157.00m20.31bn60.00k--2.6618.301.35-0.30664.8729.4814.980.55343.245.73249,950.00-0.54620.1942-0.70190.233336.4838.20-0.98690.36740.91474.250.6261,398.942.125.9497.15--0.9829.71
Illumina Inc4.43bn-3.04bn20.74bn10.59k--14.42--4.68-19.18-19.1827.949.030.49612.866.26418,224.80-34.09-6.20-45.61-7.2862.0066.39-68.71-15.480.859614.070.6087---1.756.2173.64---7.91--
Olympus Corp - ADR6.76bn196.38m21.31bn28.84k103.933.7832.013.150.17310.10475.674.760.60141.745.49234,579.501.77--2.39--66.86--2.93--1.3014.300.2437--6.16---80.69------
West Pharmaceutical Services Inc.2.88bn524.90m21.46bn10.60k42.048.3432.767.467.047.0438.6235.490.80374.265.68271,405.7014.2215.6116.9318.6535.6938.0617.7018.471.68--0.075110.692.1811.432.2823.7628.166.20
Zimmer Biomet Holdings Inc7.52bn997.10m21.64bn18.00k22.141.7111.022.884.804.8036.2262.180.35150.91415.40418,050.004.662.215.402.5271.7871.2513.277.280.6297.510.31438.906.55-1.40252.86--9.440.00
Cooper Companies Inc3.80bn359.30m21.87bn15.00k61.162.7629.725.751.801.8019.0239.800.31961.705.56253,606.703.0210.063.2911.3466.3665.549.4529.001.185.460.24930.34698.617.24-23.74-3.6615.1831.95
Steris PLC5.13bn567.70m23.83bn18.18k42.243.7621.484.645.724.0351.7364.320.49143.985.77282,395.105.455.195.955.6843.1943.6411.0910.971.497.030.266636.5613.2813.06-1.0712.6713.698.83
DexCom Inc3.93bn666.90m27.63bn9.60k43.2811.3531.677.021.591.599.386.080.57782.924.64409,875.009.798.3013.5710.5063.1665.9016.9514.142.48--0.50630.0024.4928.5658.70--28.66--
Mettler-Toledo International Inc3.75bn785.75m29.36bn16.00k38.07--32.337.8336.3436.34173.40-7.201.134.015.85234,384.6023.7423.3236.2934.0259.3358.5820.9520.510.633713.581.080.00-3.355.23-9.608.85-5.90--
Data as of Sep 18 2024. Currency figures normalised to Olympus Corp's reporting currency: US Dollar USD

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
Swiss Life Asset Management AGas of 30 Jun 20249.96k0.00%
RhumbLine Advisers LPas of 30 Jun 20248.36k0.00%
Ramirez Asset Management, Inc.as of 30 Jun 20242.59k0.00%
GAMMA Investing LLCas of 30 Jun 20241.19k0.00%
Nikko Asset Management Asia Ltd.as of 31 Dec 2023300.000.00%
PNC Investments LLCas of 30 Jun 202471.000.00%
Wetzel Investment Advisors, Inc.as of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 13 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.